Cure pharmaceutical signs agreement to develop cbd and thc oral thin films and conduct clinical studies targeting veteran health

Oxnard, calif.--(business wire)--cure pharmaceutical holding corp. (otc: curr), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with biopharmaceutical research company, (brc), an active drug enforcement administration (dea) license holder, to produce federally-compliant cannabis-based medical products. currently, cure uses its schedule 1 dea license for the development of cannabis (thc) oral film products and othe
CURR Ratings Summary
CURR Quant Ranking